Latest news with #Biotage
Yahoo
29-04-2025
- Business
- Yahoo
European Undervalued Small Caps With Insider Action In April 2025
In April 2025, European markets saw a positive shift as the pan-European STOXX Europe 600 Index rose by 2.77%, buoyed by signals from U.S. President Trump to reduce trade tensions with China. Despite some economic uncertainties, such as Germany revising its GDP forecast due to tariff impacts, the resilience of small-cap stocks in this environment can often be attributed to their agility and potential for growth within niche markets. Identifying promising small-cap stocks involves looking at companies that demonstrate strong fundamentals and strategic positioning amid these broader market dynamics. Name PE PS Discount to Fair Value Value Rating Morgan Advanced Materials 10.9x 0.5x 41.83% ★★★★★★ Tristel 27.6x 3.9x 26.76% ★★★★★☆ TT Electronics NA 0.3x 46.99% ★★★★★☆ Savills 23.9x 0.5x 43.19% ★★★★☆☆ Speedy Hire NA 0.2x 3.06% ★★★★☆☆ Seeing Machines NA 1.8x 49.22% ★★★★☆☆ Norcros 24.6x 0.6x 27.21% ★★★☆☆☆ FRP Advisory Group 12.7x 2.3x 7.31% ★★★☆☆☆ Elmera Group 11.0x 0.3x -140.30% ★★★☆☆☆ Arendals Fossekompani NA 1.6x 43.70% ★★★☆☆☆ Click here to see the full list of 68 stocks from our Undervalued European Small Caps With Insider Buying screener. Let's review some notable picks from our screened stocks. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Vp is a company engaged in equipment rental services across various sectors, with operations primarily in the UK and internationally, and it has a market capitalization of approximately £0.32 billion. Operations: The company generates revenue primarily from its UK operations (£339.21 million) and international activities (£43.35 million). Over recent periods, the gross profit margin has shown a notable increase, reaching 33.08% by September 2024, reflecting a significant improvement in cost management relative to revenue generation. Operating expenses are consistently present but vary slightly across periods, impacting overall profitability alongside non-operating expenses. PE: -43.0x Vp, a smaller European stock, is attracting attention for its potential value. Despite having high debt levels with all liabilities sourced from external borrowing, the company shows promise with an expected earnings growth of 55% annually. Insider confidence is evident as Jeremy F. Pilkington recently purchased 113,532 shares worth £638,583 in January 2025. The appointment of Richard Smith as a non-executive director signals strategic leadership changes that could drive future growth and stability. Click here to discover the nuances of Vp with our detailed analytical valuation report. Examine Vp's past performance report to understand how it has performed in the past. Simply Wall St Value Rating: ★★★☆☆☆ Overview: Biotage is a company specializing in healthcare software, with a market capitalization of approximately SEK 19.61 billion. Operations: Biotage generates revenue primarily from its healthcare software segment, with recent figures indicating SEK 1.96 billion. The company's cost structure includes significant expenses in sales and marketing, research and development, and general administrative functions. Over the periods observed, Biotage's gross profit margin has shown a trend of reaching up to 62.73%. PE: 44.2x Biotage, a smaller European company, has recently caught attention due to its SEK 1.65 per share dividend approved on April 24, 2025. The firm reported first-quarter sales of SEK 385 million, down from SEK 480 million the previous year. Despite this dip, there's insider confidence with significant buying activity observed in recent months. A proposed acquisition by Kohlberg Kravis Roberts & Co., valuing shares at SEK 145 each, suggests potential growth and industry interest despite current challenges. Get an in-depth perspective on Biotage's performance by reading our valuation report here. Gain insights into Biotage's past trends and performance with our Past report. Simply Wall St Value Rating: ★★★☆☆☆ Overview: NCAB Group specializes in providing printed circuit board (PCB) solutions and has a market cap of approximately SEK 8.53 billion. Operations: The company's revenue is primarily driven by its operations in Europe, with significant contributions from the Nordic and North American regions. Over recent periods, the gross profit margin has shown an upward trend, reaching 37.41% as of 2024-06-30. Operating expenses are a substantial part of the cost structure, with general and administrative expenses being a major component. PE: 35.1x NCAB Group, a player in the printed circuit board market, is navigating financial challenges with declining profit margins—6% this year from 9.5% last year—and high debt levels. Despite these hurdles, they project a 28.34% annual earnings growth and are actively seeking mergers and acquisitions to expand their asset-light model globally. Recent insider confidence is evident through share purchases within the past six months, signaling belief in future prospects despite current financial strains. Navigate through the intricacies of NCAB Group with our comprehensive valuation report here. Explore historical data to track NCAB Group's performance over time in our Past section. Take a closer look at our Undervalued European Small Caps With Insider Buying list of 68 companies by clicking here. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LSE:VP. OM:BIOT and OM:NCAB. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
22-04-2025
- Business
- Yahoo
KKR offers $1.2bn to buy Swedish life sciences group Biotage
Private equity firm KKR has offered to buy all shares in Swedish life sciences company Biotage for Skr11.6bn ($1.2bn). The public cash offer, via a newly formed company by KKR called RWK BidCo, is for Skr145 per share in Biotage. The offer, made on 22 April, represents a 60.1% premium on the life science group's last closing share price on 17 April. Shares in Stockholm-listed Biotage surged 36% at market open on 22 April following the offer. The company has a market cap of $1.2bn. Based on a full evaluation and assessment of the US private equity firm's takeover bid, Biotage's board has recommended to shareholders that the offer be accepted. The deal comes amid a dry patch for mergers and acquisitions involving US equity due to US President Donald Trump's tariff policy, however KKR seems to be bucking that trend. The firm stuck another sizeable healthcare deal recently, agreeing to acquire E45 maker Karo Healthcare – also Stockholm-based – for €2.6bn ($3bn) earlier in April. Biotage develops products used in drug discovery and development, including synthesisers, purification systems, and evaporators, amongst others. It also provides products for clinical and bioanalytical testing and toxicology. KKR already owns a 17% stake in Biotage through Gamma Biosciences, a life sciences tool investment platform it created in 2019. It soon could have full ownership of a company that struggled financially in the past year. Releasing its interim Q1 report on the same day, Biotage reported a sales decrease of nearly 20% compared to the same period in 2024. The life sciences group has previously highlighted the volatility within the bioprocessing market. Other big companies such as Merck's life science division MilliporeSigma has also felt the effects of the sector's low customer numbers. Despite Biotage seeing stronger demand in the drug discovery segment and peptide system manufacturing, the company deemed KKR as having 'the potential to leverage its network of industrial advisers to accelerate the company's scale-up in a private setting in the years ahead.' Although the board admitted it sees additional value held by Biotage that is not fully reflected in KKR's offer, it 'recognises that there are risks related thereto and the associated short-term volatility'. Biotage's CEO Frederic Vanderhaegen said in a statement following the Q1 results: 'We remain confident in our future mid to long-term outlook while managing the short-term headwinds with a right-sized cost base.' "KKR offers $1.2bn to buy Swedish life sciences group Biotage" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Wall Street Journal
22-04-2025
- Business
- Wall Street Journal
KKR Launches $1.2 Billion Takeover Bid For Swedish Life-Sciences Company Biotage
KKR KKR -5.24%decrease; red down pointing triangle offered to buy the shares in Biotage that it doesn't already own in a deal that values the Swedish life sciences company at $1.2 billion. The U.S. investment firm said it can provide the capital and resources needed for a strategic repositioning of Biotage to ensure future growth and value creation.
Yahoo
22-04-2025
- Business
- Yahoo
KKR makes $1.2 billion offer for Sweden's Biotage
COPENHAGEN (Reuters) -Sweden's Biotage said on Tuesday that KKR had made a cash offer for the Swedish biotechnology firm, valuing it at around 11.6 billion Swedish crowns ($1.22 billion). The offer price of 145 crowns per share represents a premium of 60.1% compared with its closing share price on April 17. Biotage's board of directors unanimously recommended to its shareholders that they accept the offer, the company said in a statement. Gamma Biosciences, which is controlled by KKR, is the company's biggest shareholder owning a 17% stake. ($1 = 9.5059 Swedish crowns) Sign in to access your portfolio
Reuters
22-04-2025
- Business
- Reuters
KKR makes $1.2 billion offer for Sweden's Biotage
COPENHAGEN, April 22 (Reuters) - Sweden's Biotage ( opens new tab said on Tuesday that KKR had made a cash offer for the Swedish biotechnology firm, valuing it at around 11.6 billion Swedish crowns ($1.22 billion). The offer price of 145 crowns per share represents a premium of 60.1% compared with its closing share price on April 17. here. Biotage's board of directors unanimously recommended to its shareholders that they accept the offer, the company said in a statement. Gamma Biosciences, which is controlled by KKR, is the company's biggest shareholder owning a 17% stake. ($1 = 9.5059 Swedish crowns)
